These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 24453033)
1. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033 [TBL] [Abstract][Full Text] [Related]
2. Investigation of circulating antibodies to ANXA1 in breast cancer. Huang Y; Zhang C; Chen C; Sun S; Zheng H; Wan S; Meng Q; Chen Y; Wei J Tumour Biol; 2015 Feb; 36(2):1233-6. PubMed ID: 25344217 [TBL] [Abstract][Full Text] [Related]
3. Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer. Wang W; Zhong W; Chen C; Meng Q; Wei J Anticancer Res; 2017 Jun; 37(6):3151-3155. PubMed ID: 28551657 [TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232 [TBL] [Abstract][Full Text] [Related]
5. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer. Liang T; Han Z; Zhao H; Zhang X; Wang Y Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332 [TBL] [Abstract][Full Text] [Related]
6. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826 [TBL] [Abstract][Full Text] [Related]
7. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer? Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933 [TBL] [Abstract][Full Text] [Related]
8. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer. Liu S; Zhang X; Jiang Q; Liang T FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378 [TBL] [Abstract][Full Text] [Related]
9. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer. Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381 [TBL] [Abstract][Full Text] [Related]
10. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma. Wang J; Xu Y; Zhao H; Zhang X J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909 [TBL] [Abstract][Full Text] [Related]
11. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer. Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790 [TBL] [Abstract][Full Text] [Related]
12. A study of circulating anti-CD25 antibodies in non-small cell lung cancer. Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913 [TBL] [Abstract][Full Text] [Related]
13. Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma. Akhtar J; Priya R; Jain V; Sakhuja P; Agarwal AK; Goyal S; Polisetty RV; Sirdeshmukh R; Kar S; Gautam P BMC Cancer; 2020 Dec; 20(1):1175. PubMed ID: 33261560 [TBL] [Abstract][Full Text] [Related]
14. FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer. Xu S; Huangfu M; Jia X; Song X; Sun B; Lee KH; Liu L; Sun S Int J Clin Oncol; 2015 Oct; 20(5):982-8. PubMed ID: 25681877 [TBL] [Abstract][Full Text] [Related]
15. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603 [TBL] [Abstract][Full Text] [Related]
16. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer. Wang T; Liu H; Pei L; Wang K; Song C; Wang P; Ye H; Zhang J; Ji Z; Ouyang S; Dai L Clin Immunol; 2020 Jan; 210():108262. PubMed ID: 31629809 [TBL] [Abstract][Full Text] [Related]
17. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Farlow EC; Patel K; Basu S; Lee BS; Kim AW; Coon JS; Faber LP; Bonomi P; Liptay MJ; Borgia JA Clin Cancer Res; 2010 Jul; 16(13):3452-62. PubMed ID: 20570928 [TBL] [Abstract][Full Text] [Related]
18. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Brichory FM; Misek DE; Yim AM; Krause MC; Giordano TJ; Beer DG; Hanash SM Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9824-9. PubMed ID: 11504947 [TBL] [Abstract][Full Text] [Related]
19. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer. Liu Y; Liao Y; Xiang L; Jiang K; Li S; Huangfu M; Sun S Int J Clin Oncol; 2017 Apr; 22(2):291-296. PubMed ID: 27778118 [TBL] [Abstract][Full Text] [Related]
20. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Jett JR; Peek LJ; Fredericks L; Jewell W; Pingleton WW; Robertson JF Lung Cancer; 2014 Jan; 83(1):51-5. PubMed ID: 24268382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]